
Rapport Therapeutics fell 1.2% from $25.11 to $24.82, behind the S&P 500's +11.2%. Its worst day was Oct 28 (−18.3%), and its low came Oct 28 at $22.50.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.72 missed the $-0.66 estimate on $0.00 revenue.
−3.0% · S&P 500 −0.2%
Rapport Therapeutics shares rose 13.0%, while the S&P 500 rose 2.9%.
Story events cover the past 12 months · Times ET
+13.0%, the year's best day · S&P 500 +2.9%
EPS of $-0.42 beat the $-0.68 estimate on $20.0M revenue (est. $8.8M).
+7.7% · S&P 500 −0.3%
EPS of $-1.19 missed the $-0.97 estimate on $0.00 revenue (est. $4.0M).
+0.6% · S&P 500 −0.2%
Rapport Therapeutics closed at its highest level of the year, 109.1% above where the year started.
+2.6% · S&P 500 0.0%
Rapport Therapeutics shares fell 17.7%, while the S&P 500 fell 0.7%.
−17.7% · S&P 500 −0.7%
Rapport Therapeutics shares fell 14.7%, while the S&P 500 rose 0.5%.
−14.7% · S&P 500 +0.5%
EPS of $-0.84 beat the $-1.22 estimate on $0.00 revenue.
+1.9% · S&P 500 +1.7%
Where it ended: a close of $24.82 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 9, 2027 (EPS est. $-0.83, revenue est. $7,140.00).
Nothing in the past 12 months.
All RAPP dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RAPP and SPY from Benzinga historical bars. Not investment advice.